97. 潰瘍性大腸炎 Ulcerative colitis Clinical trials / Disease details
臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05370885 (ClinicalTrials.gov) | May 2023 | 30/3/2022 | VE202 in Patients With Mild-to-Moderate Ulcerative Colitis | Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients With Mild-to-Moderate Ulcerative Colitis | Ulcerative Colitis;Colitis, Ulcerative | Biological: VE202;Drug: Vancomycin Oral Capsule;Other: VE202 Placebo;Other: Vancomycin Placebo | Vedanta Biosciences, Inc. | NULL | Not yet recruiting | 18 Years | 75 Years | All | 100 | Phase 2 | NULL |
| 2 | EUCTR2021-001280-24-LT (EUCTR) | 07/12/2021 | 19/08/2021 | Study of VE202 in Patients with Ulcerative Colitis | Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients with Mild-to-Moderate Ulcerative Colitis | Mild-to-moderate ulcerative colitis (UC) MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: VE202 Product Code: VE202 INN or Proposed INN: Not applicable Other descriptive name: JNJ-64841829 INN or Proposed INN: Not applicable Other descriptive name: JNJ-64841842 INN or Proposed INN: Not applicable Other descriptive name: JNJ-64841855 INN or Proposed INN: Not applicable Other descriptive name: JNJ-64841894 INN or Proposed INN: Not applicable Other descriptive name: JNJ-64841907 INN or Proposed INN: Not applicable Other descriptive name: JNJ-64841920 INN or Proposed INN: Not applicable Other descriptive name: JNJ-64841933 INN or Proposed INN: Not applicable Other descriptive name: JNJ-64841946 | Vedanta Biosciences, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 2 | Serbia;United States;Czechia;Hungary;Poland;Ukraine;Lithuania;Bulgaria;Netherlands;United Kingdom | ||
| 3 | EUCTR2021-001280-24-HU (EUCTR) | 13/10/2021 | 18/08/2021 | Study of VE202 in Patients with Ulcerative Colitis | Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients with Mild-to-Moderate Ulcerative Colitis | Mild-to-moderate ulcerative colitis (UC) MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: VE202 Product Code: VE202 INN or Proposed INN: Not applicable Other descriptive name: JNJ-72537634 | Vedanta Biosciences, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 2 | United States;Czechia;Hungary;Poland;Ukraine;Lithuania;Russian Federation;Netherlands |